Shenzhen Readline Biotechnology Co., Ltd.
PrivateLast Round
Series C
Feb 21, 2025
Total Funding Raised
$157.56M
Company Overview
Shenzhen Readline Biotechnology Co., Ltd. operates in Healthcare & Life Sciences and is based in Shenzhen. Its latest recorded funding round was a Series C round in February 2025.
Shenzhen Readline Biotechnology Co., Ltd. is a biotechnology company that develops immobilized enzyme catalytic technology and provides active ingredients for the pharmaceutical, cosmetic, and nutritional supplement industries.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Shenzhen Readline Biotechnology Co., Ltd. Comparables
Compare Shenzhen Readline Biotechnology Co., Ltd. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lansion Biotechnology Co., Ltd. | 89% | |
| Chengdu VACURE Biotechnology Co., Ltd. | 86% | |
| Assure Tech Hangzhou Co Ltd | 78% |
For institutional investors. Book with your work email.
Shenzhen Readline Biotechnology Co., Ltd. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Feb 21, 2025 | ||||
| Series B Extension | Apr 14, 2023 | ||||
| Series B | Dec 9, 2022 | ||||
| Series A Extension | Nov 22, 2021 | ||||
| Series A | Dec 4, 2020 | ||||
Angel | Jun 5, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Shenzhen Readline Biotechnology Co., Ltd. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Oriental Fortune Capital | Series B Extension, Series A Extension, Series B, Series A |
| Synergetic Innovation Fund Management | Series B Extension |
| Shenzhen Leaguer Co., Ltd. | Series A |
| Shenzhen Leaguer Venture Capital | Series A Extension |
| CoBuilder Partners | Series A Extension |
| 松禾资本 (Green Pine Capital Partners) | Series B, Series C, Series A Extension |
| CoStone Capital | Series C, Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Feb 15, 2026
Grew 18% QoQ, from 40 to 47 employees.
- Jan 21, 2026
Monthly visitors grew 41% MoM.
For institutional investors. Book with your work email.
Shenzhen Readline Biotechnology Co., Ltd. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Shenzhen Readline Biotechnology Co., Ltd.'s valuation, stock price, and market status.
Is Shenzhen Readline Biotechnology Co., Ltd. a public or private company?
Shenzhen Readline Biotechnology Co., Ltd. is a private company.
What is the current stock price of Shenzhen Readline Biotechnology Co., Ltd.?
Shenzhen Readline Biotechnology Co., Ltd. is a private company, so its shares have no public market price. Caplight tracks Shenzhen Readline Biotechnology Co., Ltd.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Shenzhen Readline Biotechnology Co., Ltd. worth (valuation)?
Valuation information for Shenzhen Readline Biotechnology Co., Ltd. is not publicly available.
Can I buy Shenzhen Readline Biotechnology Co., Ltd. stock?
Shenzhen Readline Biotechnology Co., Ltd. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Shenzhen Readline Biotechnology Co., Ltd.'s last funding round?
Shenzhen Readline Biotechnology Co., Ltd.'s most recent funding round was Series C on February 21, 2025.
Who are the main investors in Shenzhen Readline Biotechnology Co., Ltd.?
Key investors in Shenzhen Readline Biotechnology Co., Ltd. include Oriental Fortune Capital, Shenzhen Leaguer Co., Ltd., 松禾资本 (Green Pine Capital Partners), CoStone Capital.
Will Shenzhen Readline Biotechnology Co., Ltd. IPO soon?
No public IPO plans have been announced for Shenzhen Readline Biotechnology Co., Ltd..
How can I track Shenzhen Readline Biotechnology Co., Ltd. secondary market activity?
Caplight tracks bids, offers, and trades in Shenzhen Readline Biotechnology Co., Ltd.'s shares on secondary markets.